SUMMARY Plasma vasopressin sensitizes the baroreceptor reflex, whereas vasopressin given into the cerebral ventricle overrides the baroreceptor reflex by means of sympathetic stimulation. To test the hypothesis that arginine vasopressin stimulates two different receptor subtypes (V, and V 2 ) in the central nervous system, we measured the baroreceptor reflex (change in pulse interval vs change in blood pressure) after administering methoxamine (10-300 fj-glkg i.v.) in conscious rats. Animals were pretreated either with a V, vasopressin receptor antagonist administered intravenously or intracerebroventricularly, or with a V 2 receptor antagonist administered intravenously. The central V, antagonist caused sensitization of the baroreceptor reflex, whereas the intravenous V 2 antagonist attenuated it. The intravenous V! vasopressin antagonist had no effect on baroreceptor reflex sensitivity. When the experiments were repeated in rats with hereditary diabetes insipidus, neither antagonist influenced the baroreceptor reflex. Volume expansion lowered circulating vasopressin levels and also attenuated the baroreceptor reflex -effects similar to those observed with the intravenous V 2 antagonist. We conclude that vasopressin sensitizes the baroreceptor reflex through V 2 receptors accessible from the blood and inhibits the reflex through V, receptors in the brain that cannot be reached from the blood. 1 Plasma AVP induces vasoconstriction through specific receptors of the V, (vascular) subtype. However, unlike other circulating pressor hormones, such as angiotensin II, AVP increases blood pressure only at plasma concentrations well above those sufficient to produce an antidiuretic action through receptors of the V 2 (renal) subtype.
BRR by circulating AVP may take place within the carotid sinus as well as the area postrema of the brainstem. 3 4 This brain area has a relatively permeable blood-brain barrier and can therefore be reached by blood-borne AVP.
AVP produced in the supraoptic and paraventricular nuclei of the hypothalamus is transported to the posterior pituitary gland, where it is released into the circulation. In addition, AVP-containing pathways stretching from the paraventricular and suprachiasmatic nuclei to hypothalamic, limbic, brainstem, and spinal areas have been identified. 5 - 6 These pathways participate in central cardiovascular control. 5 Pharmacological studies involving application of the peptide to the ventricular space, hypothalamic nuclei, locus ceruleus, and nucleus tractus solitarii have reported marked pressor effects. 7 "" These effects were induced by stimulation of neuronal V, AVP receptors 8 and were mediated by sympathetic stimulation. 12 Furthermore, the concomitant increases in blood pressure, heart rate, and sympathetic nerve activity seen in these studies suggested that central (neuronal) AVP could override the BRR.
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To elucidate this dual action of AVP on the BRR, we tested the hypothesis that neuronal AVP and hormonal AVP constitute two opposing components of an endogenous system modulating the BRR, and that they exert opposing effects by stimulating two different AVP receptor subtypes, namely V, and V 2 receptors, within the central nervous system.
Methods
Experiments were performed in conscious male Wistar rats weighing 250 to 300 g (Thomae, Biberach, Federal Republic of Germany). Animals were kept under controlled conditions, with respect to temperature, humidity, and light periodicity. To exclude effects on BRR sensitivity that were unrelated to AVP, some of the experiments were repeated in male rats of the Brattleboro strain homozygous for hereditary hypothalamic diabetes insipidus (DI). These rats, which lack AVP, have been bred in Heidelberg since 1972. For intracerebroventricular injections, cannulae (PP20, Portex, Hythe, Kent, UK) were implanted in the lateral brain ventricle 1 to 2 weeks before the experiments, and arterial and venous catheters were inserted in the femoral artery and vein 1 or 2 days beforehand. The surgical procedures have been described previously. 13 Measurements of phasic arterial blood pressure and heart rate were performed through the arterial line with a Statham P23Db pressure transducer, Gould Brush pressure coupler, and Gould Brush 2400 recorder. BRR function was tested by subsequent intravenous bolus injections of 10, 30, 100, and 300 /ig/kg of the a,-adrenergic receptor-stimulating agent methoxamine. Blood pressure and heart rate were allowed to return to control values (over a period of at least 30 minutes) before the next dose of methoxamine was given. To evaluate BRR function, changes in systolic blood pressure were plotted against the respective changes in pulse interval between systolic blood pressure peaks (Figure 1 ). Only those recordings that were free of arrhythmias, which frequently accompanied the highest dose of methoxamine, were interpreted.
Rats were randomly allocated to groups of 7 to 10 animals each. Thirty minutes before BRR testing, Group 1 was treated intravenously with the V, receptor antagonist d(CH 2 ) 5 Tyr(Me)AVP M (10 /ng/kg bolus, followed by 4.5 /xg/kg at 30-minute intervals). Group 2 was treated intravenously with the V 2 receptor antagonist d(CH 2 ) 5 (D-Ile 2 ,Abu 4 )AVP 15 (100 fi-g/kg, followed by 30 /xg/kg at 30-minute intervals). Group 3 received the vehicle (0.9% saline) intravenously. Group 4 was given the V, receptor antagonist intracerebroventricularly (10 /xg/kg, followed by 4.5 /ug/kg at 30-minute intervals). Group 5 was pretreated with 1 ng of intracerebroventricular AVP (5 minutes before BRR testing), which had been shown to be the threshold pressor dose in previous experiments. 12 Group 6 received an intracerebroventricular injection of saline diluent.
To control for effects on the BRR due to urinary volume losses induced by renal V 2 receptor blockade, 
FIGURE 1. Measurement of baroreceptor reflex function as the relationship between an increase in systolic blood pressure and prolongation of the pulse interval after incremental intravenous doses of methoxamine in conscious rats.
Group 7 received 10 ml of 0.9% saline intravenously over 2 hours. This volume corresponded to the 10 ml of urine produced by the same dose of V 2 receptor antagonist employed, as determined in a dose-response pilot study before the actual experiments. Groups 8, 9, and 10 consisted of Brattleboro DI rats instead of the Wistar rats otherwise employed. These rats underwent the same protocol as did Groups 2, 3, and 4 (V 2 receptor antagonist intravenously, vehicle intravenously, and V, receptor antagonist, intracerebroventricularly).
Tests for specificity were performed in additional groups. Group 11 underwent volume expansion to reduce circulating endogenous AVP levels, by means of an intravenous injection of 3 ml of 1 % bovine serum albumin solution given 30 minutes before BRR testing. Group 12 was also treated with bovine serum albumin, as above; 30 minutes later, blood was collected by decapitation for measurements of plasma A VP. l6 Group 13, which was pretreated with 1 ml of 0.9% NaCl 30 minutes before sacrifice, served as the control. AVP was purchased from Bachem (Bubendorf, Switzerland). The V, and V 2 receptor antagonists were kindly supplied by Dr. M. Manning (Toledo, OH, USA). Methoxamine was purchased from Sigma (Munich, Federal Republic of Germany).
Statistical comparisons were made with a two-way analysis of variance, repeated measures when indicated, and a linear regression analysis. The slopes of the regressions were statistically compared. The 95% limits of probability were accepted as significant. Data are expressed as means ± S D . •p<0.001, compared with slope for control groups Results Linear regression analysis of the change in pulse interval versus the change in blood pressure for all groups is shown in Table 1 . Analysis of variance showed no significant differences in the resting pulse interval and blood pressure before each dose of methoxamine, either within or among the groups, indicating no effect of pretreatment on baseline values, as well as no cumulative effect of methoxamine. Baseline values and responses of systolic blood pressure and pulse interval to methoxamine, from which the regression curves were derived, are given in Table 2 . Intravenous pretreatment with the V 2 receptor antagonist significantly attenuated the BRR, as indicated by the decrease in the slope, as compared with the slope for the control group (Figure 2) . Attenuation of the BRR with V 2 receptor blockade occurred whether or not urinary volume losses were replaced by intravenous saline infusion (see Table 1 ). Volume expansion with intravenous bovine serum albumin decreased circulating AVP concentrations in the plasma from 6.1 ± 2 . 8 pg/ml in the control group to 2.8 ± 1.6 pg/ml in the experimental group (p<0.05). This regimen attenuated the BRR in a fashion no different from that of the V 2 receptor blockade (see Table 1 ).
Intravenous pretreatment with the V, receptor antagonist had no effect on BRR sensitivity (see Figure  2) . In contrast, when the V, receptor antagonist was given intracerebroventricularly, the BRR curve was significantly steeper than the slope for the controls, indicating sensitization of the reflex (Figure 3) . Conversely, intracerebroventricular pretreatment with a threshold pressordose of AVP attenuated the BRR (see Figure 3) .
In DI rats, neither intravenous pretreatment with the V 2 receptor antagonist nor intracerebroventricular pretreatment with the V, receptor antagonist affected BRR sensitivity, as indicated by the lack of change in the slope of the relationships (see Table 1 ).
Discussion
Our results demonstrate that endogenous AVP can exert a dual modulatory action on the BRR. It sensitizes the BRR by means of V 2 receptors accessible from the blood (hormonal AVP) and attenuates the BRR by means of V, receptors in the central nervous system, which cannot be reached from the blood (neuronal AVP).
Involvement of AVP V 2 receptors as mediators of BRR sensitivity is suggested by indirect evidence. In DI rats, intravenous administration of the V 2 agonist DDAVP has been reported to restore the impaired BRR function to normal. 17 Although this finding is consistent with the results presented here, we were unable to demonstrate an impaired BRR sensitivity in DI rats, as compared with Wistar rats (see Table 1 ) or with their genetic controls, the Long-Evans rats (P. Rohmeiss, unpublished observations, 1985) . However, on the basis of a dual action on the BRR by hormonal and neuronal AVP, it is conceivable that DI rats, which lack neuronal as well as hormonal AVP, have different BRR modulating systems and exhibit normal BRR sensitivity. Neither of the two AVP receptor antagonists used in this study influenced BRR sensitivity in DI rats, in contrast to the substantial effects of these antagonists in Wistar rats with normal AVP levels in plasma and brain.
Since the dose of the V 2 receptor antagonists used in this study was selected on the basis of a maximal antiantidiuretic response, we considered the possibility of a desensitization of the BRR due to V 2 antagonistinduced volume contraction. This possibility was ruled out by two control experiments. First, attenuation of the BRR by the V 2 antagonist persisted when renal volume losses were replaced. Second, volume expansion had the same effect on BRR sensitivity as the V 2 antagonist given intravenously. The attenuation of BRR sensitivity after volume expansion can be attributed to reduced plasma AVP levels under these condi- tions, indicating the importance of circulating AVP as a BRR-sensitizing factor.
The V 2 receptor antagonist could not be tested intracerebroventricularly, since it turned out to be neurotoxic in preliminary experiments. This toxicity was manifested by altered consciousness and tonic-clonic activity suggestive of seizures. A second V 2 receptor antagonist, d(CH 2 ) 5 -D-Ile-VAVP produced the same result. A V 2 receptor antagonist without central toxicity is not currently available to us. However, intracerebroventricular administration of V 2 receptor antagonists may not be obligatory in order to interpret the data. We predicate our logic on several factors. First, intracerebroventricular administration of the V, agonist DDAVP did not have significant effects on either blood pressure or heart rate (Rohmeiss et al., unpublished data, 1985) . Second, the central cardiovascular responses to AVP were blocked by a V, antagonist. 8 Finally, all experimental evidence thus far indicates that BRR sensitization is caused by blood-borne rather than brain AVP.
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Our results do not permit a precise localization of the V 2 receptor-mediated effects on BRR sensitivity. However, they are consistent with previous reports demonstrating that the carotid body and the area postrema are involved. 3 4 Since both areas can be reached from the blood, an intravenously administered antagonist may inhibit the V 2 receptor-mediated actions of circulating AVP at both sites.
In contrast to the V 2 receptor antagonist, the V, antagonist did not influence BRR sensitivity when administered by the intravenous route, although the dose was sufficient to prevent the pressor responses to exogenous AVP. 12 This finding indicates that AVP does not modulate BRR sensitivity through vascular V, receptors accessible from the blood. Conversely, when administered to the brain by central injection, the V, receptor antagonist sensitized the BRR without having any further intrinsic action on the cardiovascular system. This result suggests that the BRR is attenuated by endogenous AVP through V, receptors that cannot be reached from the circulation. The BRR inhibition observed after central application of AVP supports this conclusion.
As with the V 2 receptors, the central V, receptors remain to be localized. Indirect pharmacological evidence points to several sites within AVP-containing pathways from the hypothalamus to the brainstem, including the hypothalamus itself, the nucleus ceruleus, and the nucleus tractus solitarii. 9 "" In conclusion, our findings demonstrate that AVP, present as a neuropeptide in the central nervous system and as a hormone in the blood, can modulate cardiovascular function by direct reciprocal modulation of the BRR through its neuronal and hormonal components. In addition, our results may provide the basis for a new understanding of the role of AVP in hypertension. A discordance between the hormonal and neuronal components of the AVP system, rather than AVPmediated vasoconstriction or antidiuretic actions, may contribute to the development of hypertension through a disturbance of BRR function.
